Effect of Nitric Oxide Donor on Endothelial Progenitor Cells in Patients With Coronary Artery Disease
Coronary Artery Disease
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring Atherosclerosis, Bone Marrow, Exercise, Endothelium, Nitroglycerin, Coronary Artery Disease, CAD
Eligibility Criteria
PATIENT INCLUSION CRITERIA Adults older than 21 years. Coronary artery disease established by angiography. No myocardial infarction within 1 month. Left ventricular ejection fraction greater than 30%. No congestive heart failure symptoms within 2 months. No associated medical, neurological or orthopedic condition that might prohibit safe performance of exercise. Subject understands protocol and provides written, informed consent in addition to willingness to comply with specified follow-up evaluations. PATIENT EXCLUSION CRITERIA Significant structural heart disease (e.g. hypertrophic or dilated cardiomyopathy, valvular heart disease) as determined by echocardiography. History of recent (within 2 months) rest or nocturnal angina Organic nitrate (e.g., nitroglycerin) use other than study medication within 24 hours of exercise testing Hypersensitivity to organic nitrates. Women of childbearing age unless recent pregnancy test is negative. Lactating women. ELIGIBILITY CRITERIA - HEALTHY SUBJECTS Healthy subjects must be older than 50 years of age (to approximate the anticipated age of CAD patients), without known CAD, and be free of the following risk factors: blood pressure greater than 140/90 mmHg, fasting glucose greater than 110 mg/dL, smoking, total cholesterol greater than 250 mg/dL. Healthy subjects taking chronic prescription medications will be excluded.
Sites / Locations
- National Heart, Lung and Blood Institute (NHLBI)